Perspective Therapeutics (CATX) Cash from Investing Activities (2010 - 2026)

Perspective Therapeutics has disclosed Cash from Investing Activities across 17 years of filings, most recently posting $15.0 million for Q2 2026.

• In Q2 2026, Cash from Investing Activities rose 252.23% year-over-year to $15.0 million; the TTM figure through Jun 2026 stood at -$52.0 million (up 69.34% YoY), while the FY2025 annual figure was $41.2 million, up 118.83% from the prior year.
• Cash from Investing Activities came in at $15.0 million for Q2 2026 at Perspective Therapeutics, up from -$109.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $28.5 million in Q4 2025 to a low of -$138.6 million in Q4 2024.
• Average Cash from Investing Activities over 5 years is -$17.3 million, with a median of -$400000.0 recorded in 2023.
• Year-over-year, Cash from Investing Activities jumped 97261.54% in 2023 and sank 155632.58% in 2024.
• Over 5 years, Cash from Investing Activities stood at -$28.8 million in 2022, then surged by 99.69% to -$89000.0 in 2023, then slumped by 155632.58% to -$138.6 million in 2024, then soared by 120.59% to $28.5 million in 2025, then slumped by 47.37% to $15.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $15.0 million in Q2 2026, -$109.6 million in Q1 2026, and $28.5 million in Q4 2025.